Ispor europe 2020 programme

If you would like to book a meeting with one of our […].

Virtual ISPOR Europe 2020

Our team of market access and pricing consultants will be available at the event, giving a keynote presentation and chairing a roundtable discussion on important topics, and are providing free consultations at […].

If you would like to book a meeting with one of our experts, please contact us via discover validinsight. The global outbreak of coronavirus COVID and subsequent perception of public health risk creates challenges for international business continuity and market access planning.

In this expert led round table, we bring together key industry stakeholders to share perspectives on some of the implications and consider solutions for how to mitigate the impact on your business […]. If you would like to book a […]. Market access strategies involves the coherent actions of many functions in a pharmaceutical company.

The market access function is therefore in a balancing act to find workable and acceptable solutions for pricing, positioning, and reimbursement that fit into the short- and long-term commercial objectives. If you would like to […]. At Valid Insight, we continually look to be part of the important discussions on the trends and industry best-practices impacting pricing.

If you would like to book a meeting with one of […].

Adopt Virtual

Valid Insight, the global market access consulting company, are proud sponsors of the PharmAccess Winter Leaders Forum from 4th to 5th December in Berlin, Germany. Frank Cousins, Senior Director at Valid Insight, will be participating in a expert panel, on 4th December, entitled: Capability development for market access: Which competencies are needed in order […].

ispor europe 2020 programme

This is the must-attend event for those looking to understand and develop best practice approaches to the vital and […]. At the conference, we will be bringing our world-first market access virtual reality experience. Where you will see what happens when the market access team is grilled by the Head of Marketing about […]. If you would like […].

Лечение ВИЧ - равный консультант // АРВ-терапия, диагностика, вирусная нагрузка

Valid Insight are very excited to have had a abstract accepted for the 5th Symposium on the Megatrends in Pharmaceutical Medicine. The poster will be presented at the conference and is on the topic of: Trends in outcomes-based pricing -challenges and opportunities in adoption. To learn more about how to leverage payer engagement and data capabilities to […]. If you would […].

Ensuring market access to transformative therapies by optimising pricing, reimbursement and real-world evidence strategies is important with the increase in the number of cell and gene therapies being developed, and coming to market, globally and the potential to revolutionise the treatment of disease. To this end, Managing Director, Steve Bradshaw will be chairing the keynote […]. Join the presentation by Valid Insight entitled: Biosimilar value communication: similar or innovative?

If you would like to book a meeting, at the event, with one of our experts and learn more about how […].

Our team of Market Access and Real-World Evidence experts will be available throughout the event at booth 1. If you would like to book a meeting, at the event, with one of our experts and learn more […]. Our team of Market Access and Real-World Evidence experts will be available, at booththroughout the event which will be held at the Austria Center, Vienna. If you would like to book a meeting with […].The document was prepared in cooperation with the Slovak Society for pharmaco-economy as a reaction to a broad demand for methodological recommendations that would take account of current international trends in pharmacoeconomics as well as guidelines of international professional societies.

At the beginning ofISPOR Chapter Slovakia invited its members as well as a broader group of professionals to participate in this project. Volunteers were divided into 8 working subgroups for ensuring that each of them prepare a certain chapter of the guidelines.

Each subgroup first became familiar with the internationally accepted guidelines of professional societies e. The main focus was on existing guidelines in economically and geographically similar countries e. Draft guidelines were then presented at the Conference of Pharmaco-economics and Drug Policy in December in Bratislava.

The guidelines are based primarily on published guidelines of international professional organizations, local legislative and methodology requirements and also include other generally accepted and applied recommendations published by renowned professionals. The recommendations have in some cases a more general character than Slovak law or methodological guidelines issued by health authorities and in some cases may even differ from them, which is always explained and justified in the relevant sections.

The guidelines can serve as a methodological tool for professionals preparing or assessing pharmaco-economic analyses in Slovakia, and also for those who want to get familiar with the basic principles of pharmacoeconomic evaluation. Egypt has a current population of more than million citizens with a gross national income of USD 2, per capita according to the World Bank.

The healthcare expenditure represented only 5. Based on these data, optimizing the available resource is vital, especially with the pressing demands to improve healthcare services and minimize out-of-pocket spending. The health sector reform agenda in Egypt is focusing on quality of public health services, availability and quality of health workers and population-based disease surveillance.

Universal health insurance currently is starting to be gradually implemented all over Egypt. UHIA is the only body pooling the funds, more revenues are raised by investing in public providers and purchasing the services from GAH, while GAHAR accredits the hospitals and registers the public providers after alignment with high quality standards for health service provision.

Universal health insurance improves the access to quality health services by setting appropriate incentives to providers backed up by its strong purchasing power and defined benefits package to promote efficiency and equity, and focusing limited resources on cost-effective interventions. EU Member States agreed on March 24, on a mandate to start negotiations with the European Parliament on a legislative proposal concerning joint work on health technology assessment for the benefit of patients.

The price and reimbursement of a new medicine is a national competence within the Member States of the European Union that is carried out by Health Technology authorities. This assessment considers the added therapeutic value ATV of the drug compared to other existing therapeutics, as well as a medico-economic evaluation. ATV assessment is based on the efficacy and safety data of the drug in relation to available comparators.This must-attend event provides you with dedicated opportunities to network with your peers, HEOR experts, and thought leaders and discuss with a global audience how we establish, incentivize, and share value sustainable for health systems, patients, and technology developers.

Event Highlights:. Wed, 9 Jun - Thu, 17 Jun Thu, 10 Jun - Fri, 18 Jun Fri, 11 Jun - Mon, 14 Jun Mon, 14 Jun - Fri, 18 Jun Mon, 14 Jun - Thu, 17 Jun Mon, 14 Jun - Sat, 17 Jul Tue, 15 Jun - Fri, 18 Jun Tue, 15 Jun - Thu, 17 Jun Thu, 17 Jun - Sat, 19 Jun Thu, 17 Jun - Thu, 17 Jun Sat, 19 Jun - Tue, 22 Jun Sun, 20 Jun - Thu, 24 Jun Mon, 21 Jun - Thu, 24 Jun Mon, 21 Jun - Fri, 25 Jun There are Read more.

I am delighted to be taking over the editorial helm at HealthManagement. Today, Arab Health opened its virtual doors.Wed, 9 Jun - Thu, 17 Jun Thu, 10 Jun - Fri, 18 Jun Fri, 11 Jun - Mon, 14 Jun Mon, 14 Jun - Fri, 18 Jun Mon, 14 Jun - Thu, 17 Jun Mon, 14 Jun - Sat, 17 Jul Tue, 15 Jun - Fri, 18 Jun Tue, 15 Jun - Thu, 17 Jun Thu, 17 Jun - Sat, 19 Jun Thu, 17 Jun - Thu, 17 Jun Sat, 19 Jun - Tue, 22 Jun Sun, 20 Jun - Thu, 24 Jun Mon, 21 Jun - Thu, 24 Jun Mon, 21 Jun - Fri, 25 Jun There are Read more.

I am delighted to be taking over the editorial helm at HealthManagement. Today, Arab Health opened its virtual doors. During 2 months, until Advantecha leading provider of advanced IoT intelligence systems, By customizing the project management methodology to the unique needs Sebastian Krolop, M. The Ethica Award, the highest honour of the European cardiovascular Gamma Medica, a leader in molecular breast imaging MBI technology, announced Sat, 12 Sep Tue, 15 Sep Info Programme Registration Travel Info Mission: To promote health economics and outcomes research excellence to improve decision making for health globally.

ISPOR is the leading global scientific and educational organization for health economics and outcomes research and their use in decision making to improve health. The Society was founded in by a small group of dedicated volunteers and visionaries with the goal of serving as a catalyst for advancing the science and practice of health economics and outcomes research worldwide.

ISPOR is a nonprofit organization that welcomes all healthcare stakeholders as members, including researchers, academicians, regulators and assessors, public and private payers, healthcare providers, industry, and patient representatives. Programme will be available soon. Registration will be available soon. Travel Info will be available soon.

ispor europe 2020 programme

More events. PMWC Virtual. AcademyHealth - Annual Research Meeting. NHS ConfedExpoThe conference will question the fundamental conventions around value, risk, rewards, and the role of public and private sectors. Diagnostic testing is an essential part of modern medicine, but only recently, due to the COVID outbreak, did it gain substantial attention among the general public.

Virtual Program

Within this consortium, academic, private and inter governmental institutions collaborate in many scientific fields: ranging from microbiology and economics to sociology and data science. Inappropriate prescribing of antibiotics can lead to greater antimicrobial resistance of infectious pathogens. More rapid and accurate diagnoses can reduce inappropriate prescribing and thereby combat antimicrobial resistance.

The workshop will focus on the current state of economic models and the appraisal of point-of-care POC diagnostics, as well as provide practical guidance for modellers, in vitro diagnostic companies, and appraisal agencies to value diagnostic innovations.

ispor europe 2020 programme

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No About the workshop Purpose Diagnostic testing is an essential part of modern medicine, but only recently, due to the COVID outbreak, did it gain substantial attention among the general public.

The specific elements to consider when conceptualizing a health-economic model for POC diagnostics of infectious disease, based on a review of the literature; An example of a health-economic model to value POC diagnostics for CA-ARTI, which explains how the considerations of B were used to develop a flexible, individual-based model applicable to several European countries; The assessment of broader public health and economic benefits with respect to antimicrobial resistance over the medium- to long-term using advanced modelling techniques.

During the workshop, the audience will be asked questions using live polling, which will also be used to inform ongoing research of the VALUE-Dx project.

ispor europe 2020 programme

Tags: News. Social Media.It brought together a vibrant community of experts and thought leaders to help to shape the future of health economics and outcomes research HEOR. The theme of the meeting was Improving Health: Establishing Incentives and Sharing Valueand it sought to question the fundamental conventions around value, risk, rewards, and the role of public and private sectors.

A fundamental difference between the two is that the costs of gene therapy are incurred all at once, with a single treatment administration that aims to treat the patient for a lifetime, whereas conventional therapies will have continuous costs over time.

Events & News

How should the costs of gene therapy be distributed over time? The solution, according to speaker Professor von der Schulenburg Leibniz University Hannoverrequires novel financing approaches, especially given the uncertainty of the efficacy of gene therapies in the long term.

Determining the appropriate outcome goals will be helped by strengthening clinical trial evidence during the development planning phase. Strengthening trial evidence will also contribute greatly to the value assessment of the therapy. Decision-makers at this stage could benefit from a valuable tool to aid their assessment: Professor Drummond University of York presented a checklist for assessing gene therapies.

This included various considerations for the clinical trial evidence, such as whether surrogate endpoints were used and if historical or parallel control data were available. Overall, speakers were enthusiastic about overcoming assessment challenges to ensure gene therapies become available to the patients who need them. Expedited approvals for high-priority diseases allow treatments to get to patients faster; however, the level of evidence obtained over a shortened time period, or with fewer patients, may be less strong as a result.

This plenary session discussed the challenges of having limited evidence for health technology assessments. Speakers discussed the use of surrogate endpoints; for example, time could be saved by substituting 1-year progression-free survival in place of 2-year overall survival.

Professor Palmer spoke of the important paradigm shift that took place when a cancer drug was approved based on biomarker results alone for the first time, rather than based on outcomes directly related to the tumour site.

Also discussed was the use of causal inference frameworks in the absence of data from randomized controlled trials. Such approaches are welcomed to strengthen evidence, although Professor Dietrich reminded attendees that the decision-makers must understand these methodologies in order to make their assessment. Moderator Bettina Ryll founder of the Melanoma Patient Network Europe described her personal experiences, as a physician, of the systemic failures she encountered when her husband developed melanoma.

She outlined the need for new thinking and more holistic approaches that consider what patients really want. He highlighted the importance of investing in training advocates to ensure they are well prepared to contribute effectively to specific discussions and expressed hope for a move towards involvement of patients as full partners in healthcare decision-making. Reflecting on this, the increasing and varied role patients have played in informing decisions of the European Medicines Agency over the last 25 years was outlined by Nathalie Bere of the European Medicines Agency.

Summarizing, Dr Ryll noted that patient priorities overlap with those of other stakeholders, sometimes pharmaceutical companies and payers, but they represent a very important and independent viewpoint, and she further emphasized the benefit of providing data to support their testimonies. In particular, they reviewed basics and key concepts of modern ML techniques for descriptive, predictive and prescriptive analytics.

ML can often be confused with statistical modelling, but they are different. Generalizability is not an important factor in statistical models, but plays an important role in ML. There are a number of commonly used ML approaches: linear regression, logistic regression, support vector machines, decision trees, neural networks and random forests.I am very happy with this course. The instructors and TA were very responsive and explained the material very clearly. I appreciated having access to archives of previous discussions.

This really aided in my learning. I will be using the methodology of meta-analysis for my dissertation which is on effective schools. This will help me in my work as I am a principal of an elementary school and want to know which strategies have the greatest impact on student achievementThis is an excellent course with a lot covered (beyond expectation).

The tutor has been very responsive to queries and commentsDr. Rothstein is an excellent instructor. I have taught blended classes and know that instructor responses are crucial to the quality of discussion threads. Rothstein's responses are excellent: informative and kind. I really enjoyed this course. Great recorded lectures and materials. Questions on the discussion forums were very, very goodThe instructor, Dr.

LaBudde was highly effective. His written lectures contributed greatly to my understanding and his patient and lengthy answers to my at times overly general questions were extremely informative. It would be hard or impossible to get this information on my ownThis is a very well prepared course.

The instructor not only pointed out the right book for statisticians but also provided very useful lecture notes that helped a lotExcellent course. Smith is very dedicated, always available to answer questions, and makes this online course feel almost face-to-faceI was very anxious about taking this course. The first week was intimidating, but the readings and supplements are amazing. I am walking away really feeling like I have an introductory knowledge of statistics.

I appreciated the feedback on assignments.


thoughts on “Ispor europe 2020 programme

Leave a Reply

Your email address will not be published. Required fields are marked *